Kardigan
PublicKardigan is now publicly traded
The data on this page reflects Kardigan's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Series B
Oct 14, 2025
Total Funding Raised
$554M
Company Overview
Kardigan is a biopharmaceutical company that develops targeted cardiovascular medicines by integrating translational biology, biomarker-driven clinical trials, and AI-driven real-world data.
AI Layer
Infrastructure
Keywords
Kardigan Comparables
Compare Kardigan with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Retension Pharmaceuticals | 61% | |
| General Prognostics | 55% | |
| Cardiosense | 52% |
Kardigan Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Oct 14, 2025 | ||||
| Series A | Jan 10, 2025 |
Key People
Founding team and executive leadership
Kardigan Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Perceptive Advisors | Series A |
| HRTG Partners | Series B, Series A |
| ARCH Venture Partners | Series B, Series A |
| Fidelity Management & Research Company | Series B |
| ARCH Venture Partners | Series B, Series A |
| T. Rowe Price | Series B |
Kardigan Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access